Dynavax Technologies reported $74.03M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
TG Therapeutics TGTX:US 1.78M 332K
Abbvie ABBV:US $ 9517M 1089M
Adma Biologics ADMA:US $ 3.66M 0.15M
Agenus AGEN:US $ 25.4M 6.02M
Amgen AMGN:US $ 4677M 451M
AstraZeneca AZN:LN 9.11B 169M
Astrazeneca AZN:US 9.11B 169M
Biogen BIIB:US $ 1777.9M 295.8M
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Bristol Myers Squibb BMY:US $ 9177M 452M
Dynavax Technologies DVAX:US $ 74.03M 47.03M
Gilead Sciences GILD:US $ 5166M 549M
Glaxosmithkline GSK:US $ 6135M 283M
Merk MRK:US $ 10567M 873M
Nektar Therapeutics NKTR:US $ 19.51M 0.66M
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Novartis NOVN:VX 9.06B 463M
Pfizer PFE:US $ 15651M 1627M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Sarepta Therapeutics SRPT:US $ 179.39M 9.67M
Vertex Pharmaceuticals VRTX:US $ 1851.7M 26.53M